CD8scape: an accessible, command-line tool for predicting viral escape from the CD8+ T cell response
Discuss this preprint
Start a discussion What are Sciety discussions?Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
The CD8 + T cell response is a critical component of antiviral immunity, particularly in hosts who are immunocompromised or undergoing B cell-depleting therapy, such as rituximab. As viral evolution can lead to escape from CD8 + T cell recognition, tools that predict such escape are increasingly relevant. Here, we present CD8scape, an accessible command-line tool designed to predict viral escape from the CD8 + T cell response based on within-host sequence variation and HLA class I genotype. CD8scape is primarily a Julia wrapper for NetMHCpan v4.2, a neural network–based predictor trained on mass spectrometry–derived peptide presentation data. CD8scape integrates variant data and viral reading frames to identify all overlapping 8–11mer peptides at variant sites in both ancestral and derived states. These peptides are evaluated using NetMHCpan, which outputs eluted ligand (EL) scores as allele-specific percentile ranks to account for differences in MHC binding fastidiousness, and these are passed back to CD8scape itself. For each variant, the best-ranking peptide across all alleles is identified, and a harmonic mean is used to summarize presentation likelihood across the host’s HLA genotype. A fold-change between ancestral and derived harmonic means quantifies the likelihood of immune escape, with values >1 indicating reduced predicted presentation, and therefore a potential escape from the CD8+ T cell response. This is converted to a log 2 value of this fold-change so that the metric is symmetric around 0, with positive values representing predicted escape. CD8scape can operate with known HLA genotypes or a representative HLA supertype panel for generalizable predictions. We demonstrate our method by application to within-host SARS-CoV-2 evolution in a rituximab-treated patient and discuss its implications for population-level CD8 + T cell escape.